The AVMG Endoluminal Occlusion System is intended for arterial and venous embolization in the peripheral vasculature.

The device may be used to treat the following conditions:

- Varicocele.
- Gonadal vein treatment for pelvic varices in females with chronic pelvic pain.
- Stopping blood loss from a damaged blood vessel due to a traumatic arterial injury.
- Hemorrhage caused by a neoplasia.
- Closing an abnormal blood vessel or blood vessels supplying a vascular anomaly such as arteriovenous malformations or arteriovenous fistulas.
- Interrupting blood supply to an organ or part of an organ for permanent devascularization such as closure of the splenic artery in splenic laceration or injury.
- Devascularization of tissues involved by a neoplastic process either pre-operatively or as a palliative measure.
- Stopping gastrointestinal bleeding.

Contact Information: ArtVentive Medical Group, Inc.
2766 Gateway Road
Carlsbad, California
USA, 92009
Telephone: (760) 471-7700
Facsimile: (650) 240-1706
Email: info@artventivemedical.com  Web Site: www.artventivemedical.com

ArtVentive Medical Group, Inc. is a highly innovative, multi faceted medical device corporation dedicated to developing, manufacturing and marketing a family of endoluminal occlusion devices (EOS), enabling a minimally-invasive, immediate blockage of targeted veins, arteries and tubes within the body. The company’s corporate headquarters are located in Carlsbad California, USA.
ArtVentive Medical Group, Inc., through its proprietary technology, has developed unique minimally invasive occlusion devices and procedures bringing the current interventional image guided techniques to a new level of sophistication, resolving significant and unaddressed health issues.

The patented revolutionary device will serve in many cases as a safe and reliable alternative to major surgery. The ArtVentive EOS™ device targets a substantive market demand in several clinical areas, including peripheral and neurological vascular disorders, interventional cardiology procedures and women's health.

The EOS devices will provide an important new option for the global medical community and are expected to change the way many occlusion procedures are performed in the treatment of life-threatening conditions and diseases.

Dr. Leon Rudakov, PhD, serves as the Company's President and Chief Technology Officer. Mr. H.J. (Jim) Graham is the Chairman and Chief Executive Officer.

The Company has also attracted highly respected leaders within the medical community to its Scientific Advisory Board in addition to well-seasoned professionals in the areas of science, medical device innovation, regulatory management, manufacturing, finance, international marketing and technology.

The AVMG Endoluminal Occlusion System (EOS) device has been developed for the immediate occlusion in the peripheral arterial and venous vasculature. The system is comprised of a self expandable implantable occlusion device and a delivery catheter.

The implant is made of a Nitinol scaffold with an ePTFE occlusion cap. The scaffold is designed with radial force, sufficient to provide stiffness and strength against the vessel wall minimizing post-deployment migration.

The ArtVentive EOS™ Peripheral device is available in sizes of 6mm, serving 3.0 to 4.8mm vessels and 9mm, serving 4.5 to 7.8mm vessels (two new sizes serving vessels from 8mm-18mm is currently under development). The EOS device is loaded on a delivery catheter and is compatible with a 6F (5F is currently under development) guide catheter that tracks over a 0.035” or smaller guide wire. The implant and catheter are visible under fluoroscopy.

The EOS device is currently being evaluated in clinical investigations and has not yet been approved by regulatory authorities for commercialization.